• Greater reduction of depression symptoms at four weeks (compared to those who received a placebo and oral antidepressant)
• For the first time in 60 years, we have a new antidepressant therapy that isn’t just a spinoff of existing drugs,”
- Adam Kaplin, M.D. - psychiatrist with Johns Hopkins Medicine.
SPRAVATO® is the only FDA-approved nasal spray for treatment-resistant depression (TRD) and is covered by insurance. It is an N-methyl-D aspartate (NMDA) receptor antagonist and works differently than currently available oral antidepressants. It increases the level of glutamate in the brain which is the most abundant neurotransmitter (chemical messenger) in the brain. Glutamate is important to memory, cognition, and mood regulation.
SPRAVATO® may be used alone or together with an oral antidepressant to treat:
• Adults with treatment-resistant depression (TRD)
• Major depressive disorder (MDD) with acute suicidal ideation or behavior
Spravato® treatment is provided at VividLife Ketamine Clinic, a Spravato®-certified treatment facility. The medication is self-administered as a nasal spray under the direct supervision of a licensed healthcare provider in our private, comfortable treatment rooms.
You will be closely monitored during and after treatment for approximately two hours to ensure safety and comfort. Because Spravato® can cause temporary sedation or dizziness, you must arrange transportation home and should not drive or operate machinery until the following day.
Treatment-resistant depression (TRD)
Major depressive disorder (MDD)
Major depressive disorder (MDD) with acute suicidal ideation or behavior
Most side effects occur within one to two hours after the medication has been administered.
For the safety of patients, the clinic will closely monitor each patient for approximately two hours following the administration of the medication before they can go home.
These side effects include:
Sleepiness
Nausea
Increased blood pressure
Bad taste in mouth
Disassociation